HC Wainwright & Co. Upgrades Akebia Therapeutics to Buy, Raises Price Target to $3.75
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has upgraded Akebia Therapeutics from Neutral to Buy and raised the price target from $2 to $3.75.
August 28, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia Therapeutics has been upgraded from Neutral to Buy by HC Wainwright & Co., with a raised price target of $3.75.
The upgrade from Neutral to Buy indicates a positive outlook for Akebia Therapeutics. The raised price target from $2 to $3.75 suggests that the analyst expects the stock price to increase in the short term. This could potentially lead to an increase in the stock price as investors react to the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100